Roche Diagnostics India launches heart failure test for diabetics in India
Patients living with diabetes are at a higher risk of developing CVD:
up to 46 percent of diabetic patients will develop Coronary Vascular Disease in their lifetime which is responsible for about 50 percent of mortality in Type 2 Diebetes patients.
Roche Diagnostics India announced the launch of its point-of-care NT-proBNP test for screening diabetes patients who are at risk of cardiovascular diseases (CVD) such as heart failure (HF).
According to the company, this breakthrough innovation is designed to bring testing closer to clinics and revolutionise patient care. The claim extension of the NT-proBNP biomarker, available exclusively on the cobas h 232 system, aims to provide faster, more efficient diagnosis and management of HF in patients with type 2 diabetes (T2D), the company says.
Diabetes is associated with significant morbidity and mortality.
Recognising this critical gap, Roche Diagnostics India’s NT-proBNP test on the cobas h 232 system facilitates early detection (screening) and intervention, enabling clinicians to identify high-risk T2D patients and initiate timely treatment discussions,” the company says.
Dr. Sanjay Kalra, Chief Endocrinologist, Bharti Hospital, Karnal, India, past president of the Endocrine Society of India (ESI), and Executive Committee member & Chair, Education Working Group at the International Society of Endocrinology (ISE) said that the incorporation of NT-proBNP test extension onto convenient point-of-care platforms signifies a notable stride in diabetes care.
